JPS6022682B2 - ointment base - Google Patents

ointment base

Info

Publication number
JPS6022682B2
JPS6022682B2 JP10709277A JP10709277A JPS6022682B2 JP S6022682 B2 JPS6022682 B2 JP S6022682B2 JP 10709277 A JP10709277 A JP 10709277A JP 10709277 A JP10709277 A JP 10709277A JP S6022682 B2 JPS6022682 B2 JP S6022682B2
Authority
JP
Japan
Prior art keywords
base
ointment
ointment base
micro
separation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP10709277A
Other languages
Japanese (ja)
Other versions
JPS5441322A (en
Inventor
文夫 田中
睦 渋谷
由起子 町川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Showa Yakuhin Kako Co Ltd
Original Assignee
Showa Yakuhin Kako Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Showa Yakuhin Kako Co Ltd filed Critical Showa Yakuhin Kako Co Ltd
Priority to JP10709277A priority Critical patent/JPS6022682B2/en
Publication of JPS5441322A publication Critical patent/JPS5441322A/en
Publication of JPS6022682B2 publication Critical patent/JPS6022682B2/en
Expired legal-status Critical Current

Links

Description

【発明の詳細な説明】 本発明は安定な油性の軟膏基剤に関する。[Detailed description of the invention] The present invention relates to stable oleaginous ointment bases.

近年の医薬用の軟膏は有効性が高く、しかも安全で、か
つ官能的にもすぐれたものとなっているがその一因とし
て軟膏構成する軟膏基剤(以下基剤と略称することもあ
る)の質的向上があげられ、新規な薬物の発生及び製剤
技術の発達と相まって軟膏は著しい進歩をとげたと伝え
る。軟膏には各種のものがあり、それらを模式的に分類
すれば下記のィ〜ハに大別できる。
In recent years, pharmaceutical ointments have become highly effective, safe, and sensually superior; one reason for this is the ointment base (hereinafter sometimes abbreviated as base) that makes up the ointment. It is said that ointments have made remarkable progress, coupled with the emergence of new drugs and the development of formulation technology. There are various types of ointments, and if they are schematically classified, they can be roughly divided into the following categories.

ィ 水溶性軟膏:水落性の物質を分散煤とした親水性の
基剤に分酸質を添加した軟膏であって「練り歯磨き」な
どがその例である。
Water-soluble ointment: An ointment made by adding an acid-reducing substance to a hydrophilic base containing a water-repellent substance dispersed in soot, such as ``toothpaste.''

o 乳剤性軟膏:水、油、および表面活性剤を基礎剤と
し、乳化させて水中油型または油中水型のペースト状に
したもので、バニシングクリームが前者、コールドクリ
ームが後者の例である。
o Emulsion ointment: An emulsion based on water, oil, and a surfactant that is emulsified into an oil-in-water or water-in-oil paste, with vanishing cream being an example of the former, and cold cream being an example of the latter. .

これらを基剤とする軟膏は基剤の製造過程中において主
楽を加えられる。ハ 油脂性軟膏:水の不溶性の油脂性
物質を分散嬢とした基剤であって該基剤は疎水性であり
、これに主薬をはじめ他の分散質が添加される。
Ointments based on these are supplemented during the manufacturing process of the base. C. Oil-based ointment: A base containing a water-insoluble oil-based substance as a dispersant, and the base is hydrophobic, to which the main drug and other dispersoids are added.

本発明の軟骨基剤は上記のィ〜ハのうちハの範ちゆうに
入る軟膏に適用されるものであるが尚、具体的にいえば
流動パラフィン(以下流パラと略称)が構成分中に含ま
れる。石油系の基剤に応用されるものである。該石油系
基剤のもつ一般的な特徴は下記のように要約される。即
ち該基剤は長い歴史をもつ重要な基剤であるがその理由
としては石油系の物質は粘度、鋼度、色調、又はイb学
組成などの物性を異にする数多くの穣類が入手可能であ
り、しかもそれらの品質は品種ごとにほとんど一定のも
のが得られるため、縞要家は所望の種類を自由に、しか
も品質上の心配なく入手し、目的の基剤を調製し得るこ
と:又、該基剤は化学的、物理的に安定性が高く、配合
される薬剤との相互作用も少いこと;及び患部に適用さ
れた際に生理的に不活性で、かつ生体側への薬剤の放出
性が良にことなどがあげられる。
The cartilage base of the present invention is applied to ointments that fall into category C of the above A to C, but specifically, liquid paraffin (hereinafter abbreviated as liquid paraffin) is a component. include. It is applied to petroleum-based base materials. The general characteristics of the petroleum base are summarized as follows. In other words, this base material is an important base material with a long history, and the reason for this is that petroleum-based substances are available in many varieties with different physical properties such as viscosity, hardness, color tone, and chemical composition. This is possible, and since the quality of these products is almost constant for each variety, the master can freely obtain the desired variety and prepare the desired base without worrying about quality. : Also, the base has high chemical and physical stability, and has little interaction with the drugs it is mixed with; and it is physiologically inert when applied to the affected area and has no effect on the living body. For example, it has good drug release properties.

これだけの長所を有する基剤であるがしかしながら不満
な点がないわけではない。これを少しく詳細に説明すれ
ば、以下の様である。‘1’従来技術の石油系軟膏基剤
の欠点として挙げられる最も単純な軟膏基剤の例は、流
パラに対し常温で間型の石油形ラックス、例えばワセリ
ン、マイクロクリスタリンワツクス(以下マイクロWと
略称)、固型パラフィン等を単独、または組合わせて加
熱溶融せしめた基剤であ。
Although this base has many advantages, it is not without its drawbacks. This will be explained in a little more detail as follows. '1' The simplest example of an ointment base that can be cited as a disadvantage of petroleum-based ointment bases in the prior art is petroleum-based laxatives that are stable at room temperature, such as vaseline and microcrystalline wax (hereinafter referred to as micro-W). It is a base made by heating and melting solid paraffin, etc., alone or in combination.

該基剤は外部環境温度(以下単に温度と略称)に対する
鋼度の変化が大きく、更に常温における該基剤の組成は
均質でなく、ワックスの結晶が単に流パラ中に分散して
いるにすぎず、ワセリンの処方量が少いほど短時間内に
蓬時的な変化を生じ流パラの分離は避けられない。該分
離の防止のためには次の【2;項に挙げられる従来技術
の軟膏基剤との折衷が、行われるがただし完壁を期しが
たい。■ 流パラに10%前後の軟質無水ケイ酸ないい
まその他の微粒子の粉体を加えて、ペースト状に成形し
て基剤とする。
The hardness of the base material changes greatly depending on the external environmental temperature (hereinafter simply referred to as temperature), and the composition of the base material at room temperature is not homogeneous, with wax crystals simply being dispersed in the liquid. First, the smaller the amount of vaseline prescribed, the more time-consuming changes will occur within a short period of time, and separation of fluids will be inevitable. In order to prevent such separation, compromises with the prior art ointment bases listed in item (2) below are attempted, but it is difficult to expect perfect performance. (2) Add about 10% of soft silicic anhydride or other fine particle powder to the liquid and form it into a paste to use as a base.

該基剤は温度に対する鋼度の変化が小さいなどの変化を
もつが、流パラ分離は例えば上記{1}の従釆技術の軟
膏との折衷によっても避けられない。尚、該分離は調度
の低い場合に著しく、高い場合に少くなるが、それより
も重要なことは分散質の影響によって患部における薬剤
の放出性が抑制される点にあり、従って軟膏基剤も又必
ずしも満足すべき基剤ではない。‘3} 上記{1}及
び【2}項の従釆技術の軟膏基剤の欠点を改善するため
流パラに低重量のポリエチレン又は高級脂肪酸のアルミ
ニウム塩などを加え、150qo前後に加熱して溶解せ
しめたのちに急冷して得た基剤が実用されている。
Although the base material has changes such as a small change in steeliness with respect to temperature, flow separation cannot be avoided even by, for example, a compromise with the ointment of the conventional technique described in {1} above. This separation is noticeable when the preparation is low and decreases when the preparation is high, but what is more important is that the release of the drug in the affected area is suppressed by the influence of the dispersoid, and therefore the ointment base is also Moreover, it is not necessarily a satisfactory base. '3} In order to improve the drawbacks of the ointment base of the sub-techniques described in {1} and [2] above, low weight polyethylene or aluminum salts of higher fatty acids, etc. are added to Narupara and dissolved by heating to around 150 qo. A base obtained by cooling and then quenching is in practical use.

代表的なものは前者(ポリエチレン)の例であってプラ
スティベース(米国:スクィブ社製造の軟膏基剤の商標
名)と称され、全世界ですでに20王以上の使用実績が
ある。該基剤は石油系基剤のもつ前述の優れた特徴をほ
とんど満足するものであるが、唯一の欠点として、他の
従来技術の石油系基剤と同機に(その程度は僅かである
が)流パラ僅かに分離することが避けられず、特に製造
工程における熱管理が不完全な場合には著明な該分離を
示すことがある。尚、該基剤のポリエチレンは流パラの
中に安定なマトリックスを作って、流パラをペースト状
に増粘しており、このマトリックスは60qo以上に加
溢されたり機械的な力を加え続けられたりすると恒常性
を失い、ポリエチレンは凝集し、流パラは完全に分離す
るという本質的な欠点を有する。それ故に加熱滅菌はも
とより、熱時溶解の薬剤との配合、長時間を要する研和
の工程などは禁忌である。 .以上(1
1〜【即こおける従来技術の軟膏基剤に共通する欠点と
してはこれを「分離」に要約することができる。
A typical example is the former (polyethylene), which is called Plastibase (trade name of an ointment base manufactured by Squibb Company in the United States), and has already been used in more than 20 cases around the world. Although this base satisfies most of the above-mentioned excellent characteristics of petroleum-based bases, the only drawback is that it is not as good as other conventional petroleum-based bases (although to a lesser extent). Slight separation of the flow rate is unavoidable, and may be noticeable especially if heat management in the manufacturing process is incomplete. Furthermore, the base polyethylene forms a stable matrix within the ryupara, thickening the ryupara into a paste-like consistency, and this matrix cannot be overflowed to more than 60 qo or subjected to continuous mechanical force. The essential drawback is that if the polyethylene is used, it will lose its homeostasis, the polyethylene will coagulate, and the liquid will completely separate. Therefore, not only heat sterilization but also combinations with drugs that dissolve when heated, and lengthy polishing processes are contraindicated. .. or more (1
1 - [Common shortcomings of the prior art ointment bases that can be applied immediately can be summarized as ``separation''.

本発明者らは先に述べた石油系基剤のもつ特徴を生かし
ながら尚かつ分離を全く生じない基剤を得るため、流パ
ラとマイクロWとの混合物の組成について研究した。
The present inventors studied the composition of a mixture of Ryupara and Micro W in order to obtain a base that does not cause any separation while taking advantage of the characteristics of the petroleum base described above.

即ち流パラとマイクロWとを加温溶融後に冷却して得た
基剤は透明感のあるキメ細いペースト状をなし外観的に
も官能的にもすぐれた基剤であるが、上文‘1}にも記
したごと〈温度に対する鋼度の変化が大きいことと、流
パラの分離が避けられなかったこととの欠点を示した。
そこで本発明者らはこれらの対策のために上文‘2}の
軟膏基剤を応用したのであるが、軽質無水ケイ酸を添加
すると鋼度が高くなり分離は一応防止し得たが、逆に加
溢しても鋼度の低下が少ないので、製造工程において不
便であると判断された。次に本発明者らは上文(3}の
技法のごとく熱時溶解したのち冷却し、室温にて安定な
基剤を形成する物質を探索する研究を行った結果、該目
的を達成する添加物質はデキストリン脂肪酸ェステル(
以下OFAと略称)(好ましくはカィハッ化学KK:商
標名RheopeariKE)のみであることを発見し
、本発明を完成した。又マイクロWの代りにワセリンを
使用しても本発明の特徴としての上記のDFAの添加に
より流パラとワセリンとの分離を起すことのない軟膏基
剤を得ることができる。
That is, the base obtained by heating and melting Ryupara and Micro W and then cooling it is a transparent, fine-textured paste-like base that is excellent both in appearance and sensuality. } As mentioned above, the disadvantages were the large change in steel hardness with temperature and the unavoidable separation of flow particles.
Therefore, the present inventors applied the ointment base described in ``2'' above to counter these problems, but adding light silicic acid anhydride increased the steel strength and was able to prevent separation to a certain extent, but the opposite effect occurred. It was judged that this was inconvenient in the manufacturing process because there was little decrease in steel strength even if it was flooded with water. Next, the present inventors conducted research to search for a substance that melts under heat and then cools down to form a stable base at room temperature, as described in technique (3) above. The substance is dextrin fatty acid ester (
(hereinafter abbreviated as OFA) (preferably Kaiha Kagaku KK (trade name: RheopeariKE)), and completed the present invention. Furthermore, even if petrolatum is used instead of Micro-W, an ointment base can be obtained that does not cause separation of petrolatum and petrolatum due to the addition of the above-mentioned DFA, which is a feature of the present invention.

尚、マイクロWとワセリン化学的本質については、マイ
クロWとワセリンは共に石油から得られた非流動性炭化
水素の混合物であるが、前者は微細結晶質の固型(柔軟
な塊)であるのに対し、後者は半固型(ペースト状)の
非晶質である。流パラ対マイクロWの組成比及び流パラ
対ワセリンの組成比を3対1、2対1及び1対1とした
場合の組成物から液状物質の分離防止を達成するための
DFAの最小添加率を測定して表一1の結果を得た。
Regarding the chemical nature of Micro-W and petrolatum, both Micro-W and petrolatum are mixtures of non-flowing hydrocarbons obtained from petroleum, but the former is a fine crystalline solid (a flexible lump). On the other hand, the latter is semi-solid (paste-like) and amorphous. Minimum addition rate of DFA to achieve prevention of separation of liquid substance from the composition when the composition ratio of Narupara to Micro W and the composition ratio of Narupara to Vaseline are 3:1, 2:1, and 1:1 were measured and the results shown in Table 11 were obtained.

表−1 組成比とDFAの添加率 流パラ、DFA及びマイク。Table-1 Composition ratio and addition rate of DFA Ryupara, DFA and Mike.

Wの混合物において鋼度は手として流パラとマイクロW
との配合比でさまり組成物中のマイクロWは「粘り」を
与える役目をもつ。表−1の結果から、本発明によるD
FA添加は分離防止の目的をもって使用されるが例えば
20午○で半流動状であるところの流パラ:マイクロW
=3:1の場合についてはDFAの該目的のための添加
率として2%が必要であり、同様に20午Cで軟膏よう
の調度となる流パラ:マイク。W=1:1の場合につい
は1%の添加で該目的を達成し得ることが判る。マイク
ロWの代りにワセリンを用いた場合にも本発明が応用さ
れ得るものであってワセリン使用時のDFAの添加効果
はマイクロW使用時のDFA添加効果ほど著大ではない
がた)、しワセリンの場合にも又DFAの添加により分
離防止を達成し得る。
In the mixture of W, the steel strength is as follows: Flow Para and Micro W
Micro W in the composition has the role of imparting "stickiness". From the results in Table 1, D according to the present invention
FA addition is used for the purpose of preventing separation, but for example, when the flow is semi-fluid at 20 pm, Micro W
In the case of =3:1, 2% of DFA is required for the purpose, and similarly, the ratio of DFA to be used as an ointment at 20 pm C: Mike. It can be seen that in the case of W=1:1, the objective can be achieved by adding 1%. The present invention can also be applied when petrolatum is used instead of Micro W, and the effect of adding DFA when using petrolatum is not as significant as the effect of adding DFA when using Micro W). Prevention of segregation can also be achieved by adding DFA.

表一1から流パラとワセリンとの3:1の混合物は20
ooで半流動状であり、この場合の分離防止のために加
えられるDFAは5%以下では効果なく、少なくとも6
%以上の添加が必要であって、20午0で軟膏ようの鋼
度となるところの流パラ:ワセリンとの1:1の混合物
については2%の添加が該目的達成のために必要である
ことが理解される。本発明によるDFA添加効果(即ち
軟膏基剤組成物からの液状物質分離の防止効果)は次の
ようにして証明された。
From Table 1, a 3:1 mixture of ryupara and petrolatum is 20
oo is in a semi-liquid state, and DFA added to prevent separation in this case is ineffective at less than 5%, and at least 6% DFA is added to prevent separation.
For a 1:1 mixture with vaseline, an addition of 2% is necessary to achieve the objective. That is understood. The effect of adding DFA according to the present invention (ie, the effect of preventing separation of liquid substances from the ointment base composition) was demonstrated as follows.

即ち表−1に示された流パフ、マイクロW及びDFAの
組成物のA、B並びCの3種試料と夫々の対照物(DF
A不含)とについて各誌料を容量50泌のビーカーにと
り、スパーテル中心部を円錐状にかきとり、ビーカー内
に凹部(円錐状の空所)を形成させ、この円錐の頂端が
ビーカーの底部に達し、円錐の池端がビーカーの上縁付
近に達するようにし、370の陣温器中に一定期間放置
した後に温時ビーカーを預け、分離して上記の凹部に溜
った液状物質を時計皿に流し取り、その重量を重り、表
−2に示す結果を得た。表−2 分離した液状物質の量
(燐) 本発明の基剤の特徴は以下に要約される。
That is, three types of samples A, B, and C of the compositions of flow puff, Micro W, and DFA shown in Table 1 and their respective controls (DF
For A), place each magazine material in a beaker with a capacity of 50 volumes, scrape off the center of the spatula in a conical shape, and form a recess (conical cavity) in the beaker, with the top of this cone reaching the bottom of the beaker. , so that the edge of the conical pond reaches near the upper edge of the beaker, and after leaving it in the 370 thermostat for a certain period of time, place the warming beaker in it, separate it, and pour out the liquid substance that has accumulated in the recess into the watch glass. , and the results shown in Table 2 were obtained. Table 2 Amount of liquid substance separated (phosphorus) The characteristics of the base of the present invention are summarized below.

{1} 流パラ、マイクロWのごとき化学的に安定でか
つ生理的に不活性な物質を基本とする。
{1} Based on chemically stable and physiologically inert substances such as Ryupara and Micro W.

‘2} 軟膏基剤のままの場合、又は数%以下の薬剤を
加えた軟膏の場合、ないいま適宜粉体を加えてパスタ剤
を製した場合など、いずれの場合にも温度に対する安定
性は高く通常、医薬品の保存される状態においては分離
は生じない。
'2} In either case, whether it is an ointment base as it is, an ointment with a few percent or less of a drug added, or a pasta preparation made by adding appropriate powder, the stability against temperature is Separation does not normally occur under the conditions in which pharmaceutical products are stored.

‘3ー 軟膏基剤の組成が流パラ、マイクロWおよびD
FAの三成分という単純なものであり、流パラを増量し
たマイクロWを減量すれば鋼度は低下し、その逆を行え
ば鋼度が上りかつ「ねばり気」が出、DFAを増量すれ
ば固さが増すので任意の配合比を選び所望の軟膏基剤を
得ることが可能である。
'3- The composition of the ointment base is Ryupara, Micro W and D.
It is a simple three-component of FA, and if you reduce the amount of Micro W that has increased flow parameters, the steeliness will decrease; if you do the opposite, the steeliness will increase and "stickiness" will appear, and if you increase the amount of DFA, the steelness will decrease. Since the hardness increases, it is possible to select any blending ratio to obtain a desired ointment base.

‘41 軟膏基剤の上記の三成分は、これらを1000
0に加溢して濃伴溶融せしめたのち室温に冷却するだけ
で基剤と成すことができるので熱管理が容易であり、か
つ、加温−溶融−冷却−凝固は可逆的である。
'41 The above three components of the ointment base are
Since the base material can be prepared by simply flooding the base material to 0 and cooling it to room temperature, heat management is easy, and the heating-melting-cooling-solidification process is reversible.

従って基剤の無菌化が可能である。【51配合される薬
剤との相互作用がなく、薬剤の放出性もよいので軟膏か
ら生体側への薬剤の放出性がよい。
Therefore, the base material can be sterilized. [51] Since there is no interaction with the compounded drug and the drug release property is good, the drug release property from the ointment to the living body side is good.

‘6} 基剤の成分が単純であり、熱管理も簡単、製造
設備も簡素であるのでコストも低廉であり、従来設備を
そのまま使用することができる。本発明の軟管基剤の利
用面として次の二点が拳げられる:【a} 本発明で得
られた基剤は、従来より用いられていた疎水性の石油系
基剤を使用する軟膏に対して応用され、例えば合成富。
'6} The base ingredients are simple, heat management is easy, and the manufacturing equipment is simple, so the cost is low, and conventional equipment can be used as is. The following two points can be highlighted regarding the use of the soft tube base of the present invention: [a] The base obtained according to the present invention can be used in ointments using conventionally used hydrophobic petroleum bases. Applied to, for example, synthetic wealth.

賢皮質ステロイド軟膏、加熱滅菌を要する眼軟膏の基剤
に応用されることができる。【bー 鋼度の低い基剤が
容易に得られ、該基剤は、練合或は研和などの機械的操
作によっても恒常性が害われないばかりでなく亜鉛岸華
、けいそう士、ゼラチン、CMCナトリウム、ポリアク
リル酸ナトリウムまたはデキストリンなどとの配合が禁
忌でないため、これらの粉体(粘着性粉体)を単独でな
いしは2種類以上を組合わせて40〜50%となるよう
に練和したパスタはこれに対し抗生物質、殺菌剤、酸素
ないいま各種ホルモンを配合することにより、用時口腔
内粘膜上に塗布し粘着せしめるいわゆる口腔用パスタ剤
として応用されることができる。
It can be applied as a base for corticosteroid ointment and eye ointment that requires heat sterilization. [b- A base material with a low steel content can be easily obtained, and the base material not only does not have its homeostasis damaged by mechanical operations such as kneading or grinding, but also has a low steel content. Since blending with gelatin, CMC sodium, sodium polyacrylate, dextrin, etc. is not contraindicated, these powders (sticky powders) may be kneaded alone or in combination of two or more to a concentration of 40 to 50%. By adding antibiotics, bactericidal agents, oxygen, and various hormones to the softened pasta, it can be applied as a so-called oral pasta preparation, which is applied to the oral mucosa and adhered to the oral mucosa at the time of use.

次に実施例により本発明の態様を説明するが該実施例は
単なる例示であって本発明を限定するものではない。
Next, embodiments of the present invention will be explained with reference to Examples, but these Examples are merely illustrative and do not limit the present invention.

実施例 1 流パラ(国産化学KK製、比重0.855以上)1.5
k9にDFA30夕及びマイクロW(米国:ゾンネボー
ン社製)1.0k9を加えて100つ0の蒸気浴で縄拝
しながら加溢し全質均等に溶融した後にポアサィズ3A
のフィルターで炉過し室温に冷却する。
Example 1 Ryūpara (manufactured by Domestic Chemical KK, specific gravity 0.855 or more) 1.5
DFA30 and Micro W (manufactured by Sonneborn, USA) 1.0k9 were added to k9, and the mixture was heated in a steam bath at 100°C to allow it to melt evenly, and then the pore size was 3A.
Filter through a furnace and cool to room temperature.

冷却の過程で適当な容器に分注し軟膏基剤として使用す
るか又はこれを市販に供する。実施例 2 流パラ(実施例1に使用されたものと同じ)1.0k9
にDFA40夕及びワセリン(日本薬局方)1.0k9
を加え、100ooの蒸気格で縄拝しながら加温し、以
下は実施例1と同様に処理し、軟膏剤の基剤として使用
するか又はこれを市販に供する。
During the cooling process, the mixture is dispensed into suitable containers and used as an ointment base, or sold commercially. Example 2 Ryu Para (same as used in Example 1) 1.0k9
DFA40 and Vaseline (Japanese Pharmacopoeia) 1.0k9
The mixture was heated at a steam rate of 100 oo, heated in the same manner as in Example 1, and used as a base for an ointment or sold commercially.

本発明の関連事項を以下の通りに記載する。1 流動パ
ラフィン及び非流動性鉱油系ワックスの混合物に対し、
少割合のデキストリン脂肪酸ェステルを加え、約100
午0の温度の下に全質均等に溶融された後に冷却して得
ることを特徴とする安定な軟膏基剤の製法。
Matters related to the present invention will be described below. 1 For a mixture of liquid paraffin and non-flowing mineral wax,
Add a small percentage of dextrin fatty acid ester, about 100
1. A method for producing a stable ointment base, which is obtained by uniformly melting the entire material at a temperature of 1:00 pm and then cooling it.

Claims (1)

【特許請求の範囲】 1 下記の三成分即ち(a)流動パラフイン、(b)非
流動性鉱油系ワツクス及び(c)デキストリン脂肪酸エ
ステルからなることを特徴とする安定な軟膏基剤。 2 非流動性鉱油系ワツクスがマイクロクリスタリンワ
ツクスである特許請求の範囲第1項に記載の安定な軟膏
基剤。 3 非流動性鉱油系ワツクスがワセリンある特許請求の
範囲第1項に記載の安定な軟膏基剤。 4 流動パラフインとマイクロクリスタリンワツクスと
の含量に対しデキストリン脂肪酸エステルが少なくとも
1重量%に加えられている特許請求の範囲第2項に記載
の安定な軟膏基剤。 5 流動パラフインとワセリンとの含量に対しデキスト
リン脂肪酸エステルが少くとも2重量%に加えられてい
る特許請求の範囲第3項に記載の安定な軟膏基剤。
[Scope of Claims] 1. A stable ointment base comprising the following three components: (a) liquid paraffin, (b) non-liquid mineral oil wax, and (c) dextrin fatty acid ester. 2. The stable ointment base according to claim 1, wherein the non-flowing mineral oil-based wax is a microcrystalline wax. 3. A stable ointment base according to claim 1, wherein the non-flowing mineral oil-based wax is petrolatum. 4. A stable ointment base according to claim 2, in which at least 1% by weight of dextrin fatty acid ester is added to the content of liquid paraffin and microcrystalline wax. 5. A stable ointment base according to claim 3, in which at least 2% by weight of dextrin fatty acid ester is added to the content of liquid paraffin and petrolatum.
JP10709277A 1977-09-06 1977-09-06 ointment base Expired JPS6022682B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP10709277A JPS6022682B2 (en) 1977-09-06 1977-09-06 ointment base

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10709277A JPS6022682B2 (en) 1977-09-06 1977-09-06 ointment base

Publications (2)

Publication Number Publication Date
JPS5441322A JPS5441322A (en) 1979-04-02
JPS6022682B2 true JPS6022682B2 (en) 1985-06-03

Family

ID=14450249

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10709277A Expired JPS6022682B2 (en) 1977-09-06 1977-09-06 ointment base

Country Status (1)

Country Link
JP (1) JPS6022682B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0422690Y2 (en) * 1986-03-11 1992-05-25

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3502574B2 (en) * 1999-06-29 2004-03-02 東亜薬品株式会社 Eye ointment for treatment of eye infections
WO2015152168A1 (en) * 2014-03-31 2015-10-08 マルホ株式会社 Ointment base and ointment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0422690Y2 (en) * 1986-03-11 1992-05-25

Also Published As

Publication number Publication date
JPS5441322A (en) 1979-04-02

Similar Documents

Publication Publication Date Title
JP3963338B2 (en) Treatment agent for decolorizing hair
US4310516A (en) Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
AU692815B2 (en) Novel foaming compositions, particularly for rectal foams, and resulting foams
JPS62111922A (en) Drug composition
JPS5849599B2 (en) liquid detergent composition
CA2212309C (en) Extended-release solid oral dosage forms of drugs having low solubility in water
JPS58216728A (en) Dispersant for pearl brightener
RU2694530C2 (en) Method of producing liquid pharmaceutical suspensions containing bismuth
Pokharkar et al. Development and optimization of eugenol loaded nanostructured lipid carriers for periodontal delivery
EP1094791B1 (en) Thixotropic formulations for filling capsules
US4436738A (en) Stabilized estradiol cream composition
JPS6022682B2 (en) ointment base
JPS61194013A (en) Anti-sunburn cosmetic
JPH0476729B2 (en)
JP5650434B2 (en) Granular bath
JPS60109519A (en) "nifedipine(r)" composition and production thereof
Duclos et al. Rheology of polyol behenates and drug release from matrix monolithic capsules
JPS60166604A (en) Preparation of weakly acidic w/o/w-type emulsion cosmetic
JPS6032601B2 (en) Pharmaceutical suspension for gelatin capsules
JPS6156040A (en) Production of fluid composition of water-in-oil type emulsified oil
JPH0314813B2 (en)
JPH0140806B2 (en)
IE912201A1 (en) Amantadine hydrochloride suspension with enhanced¹dissolution characteristics for use in soft gelatin capsules
JPS63390A (en) Solid lubricant
JPH02277542A (en) Aqueous suspended composition